Gilead Sciences stock rises after FDA clears Bixlenvo
Published on 08/29/2026 at 14:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences, Inc. (ISIN US3755581036) stock rose after the U.S. FDA cleared Bixlenvo on August 28, 2026, while the shares closed at $145.68 on August 28, 2026 and carried a market value of $180.64 billion.
The move gives investors a fresh catalyst to measure against the company's latest quarter, which delivered $7.80 billion in revenue and an earnings result of $(6.75) per share versus the $(7.25) consensus estimate. Revenue increased 10.6 percent from the same quarter a year earlier.
FDA approval and pricing
The approval centers on Bixlenvo, a once-daily oral combination pill for adults living with HIV whose virus has already been reduced to very low levels. The wholesale acquisition cost for a 30-day supply is $4,595, and the product is intended for patients on complex regimens or those who cannot use current single-tablet options.
That pricing matters because it adds a commercial anchor to the launch just as Gilead is trying to extend its HIV franchise. The company said the regimen combines bictegravir 75 mg and lenacapavir 50 mg.
Quarterly numbers
The August 3, 2026 quarter showed a wider accounting loss than a year earlier, when Gilead posted $2.01 in earnings per share for the same period, but the top line still expanded to $7.80 billion from the prior year's level. Analysts now expect full-year earnings of -0.5 per share, while the current consensus price target stands at $158.04.
For investors, the key comparison is straightforward: the quarter beat revenue expectations by $400 million and EPS by $0.50, while the stock still traded below the latest consensus target after the August 28 session.
Product focus
Bixlenvo sits inside Gilead's broader HIV portfolio, where long-acting and simplified regimens remain the main commercial thread. The launch gives the company another treatment option in a market that rewards adherence and regimen simplicity.
Shares and setup
Gilead Sciences stock traded at $145.68 on August 28, 2026, after opening at $149.47 and moving between $144.88 and $149.47 during the session. The Nasdaq Biotechnology Index closed at 7,133.52 on August 28, 2026, down 2.54 percent, which left Gilead's move looking firmer than the sector backdrop.
Company
Company: Gilead Sciences, Inc.
ISIN: US3755581036
Ticker: GILD
Exchange: Nasdaq Global Select Market
Price (as of August 28, 2026, 4:00 p.m. ET): $145.68 USD
Market cap: $180.64 billion
Sector / Industry: Health Care / Biotechnology
Index membership: NASDAQ Biotechnology
